Previous Choice report exposes ideologically-driven claims against pharmacy: Guild
Next Consumers Health Forum worried on biosimilars

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

1 Comment

  1. Dr Catherine Pratt
    10/07/2015

    Benitec an Australia company
    has designed a ddRNAi–based multi-cassette vector called TT-034, which
    targets 3 parts of the HCV genome with a single intravenous dose. TT-034
    has achieved over 90% transfection of liver cells and, by targeting 3
    separate, well-conserved regions of HCV simultaneously, it prevents
    generation of drug-resistant mutants, a major problem in the treatment
    of Hepatitis C. TT-034 is also designed to cause liver cells to continue
    to produce molecules that ‘turn off’ replication of HCV, for as long as
    the liver cells persist, thus conferring protection from re-infection
    for months or potentially years, from a single dose.

Leave a reply